The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
Jieun YangSe Hyun KimEun Hee JungSang-A KimKoung Jin SuhJi Yun LeeJi-Won KimJin Won KimJeong-Ok LeeYu Jung KimKeun-Wook LeeJee Hyun KimSoo-Mee BangJong Seok LeePublished in: Thoracic cancer (2022)
Concurrent use of metformin and DPP4 inhibitors with ICIs significantly improved the clinical outcomes without increasing the incidence of irAEs in NSCLC.